The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
We expect the Asia Pacific dry eye syndrome market to exhibit a CAGR of 7.81% during 2022-2027.
The rising environmental pollution levels, along with the prolonged and excessive screen time through laptops, smartphones, and television, is primarily driving the Asia Pacific dry eye syndrome market.
The sudden outbreak of the COVID-19 pandemic had led to postponement of elective treatments for dry eye syndrome to reduce the risk of the coronavirus infection upon hospital visits or interaction with healthcare professionals and medical equipment across several Asia Pacific nations.
Based on the disease type, the Asia Pacific dry eye syndrome market has been divided into evaporative dry eye syndrome and aqueous dry eye syndrome, where evaporative dry eye syndrome currently exhibits a clear dominance in the market.
Based on the drug type, the Asia Pacific dry eye syndrome market can be categorized into anti-inflammatory drugs, lubricant eye drops, and autologous serum eye drops. Currently, anti-inflammatory drugs account for the majority of the total market share.
Based on the product, the Asia Pacific dry eye syndrome market has been segregated into liquid drops, gel, liquid wipes, eye ointment, and others. Among these, liquid drops currently hold the largest market share.
Based on the distribution channel, the Asia Pacific dry eye syndrome market can be bifurcated into hospital pharmacies, retail pharmacies, and online pharmacies. Currently, hospital pharmacies exhibit a clear dominance in the market.
On a regional level, the market has been classified into China, Japan, India, South Korea, Australia, Indonesia, and others, where China currently dominates the Asia Pacific Dry Eye Syndrome market.
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at